Gitelman Syndrome – Clinician Information
Gitelman Syndrome (GS) is typically characterized by hypokalemic metabolic alkalosis with significant hypomagnesemia and low urinary calcium excretion.
GS may appear in childhood, but is more frequently diagnosed in adolescence or adulthood. Symptoms are widely variable both in nature and severity. The commonest are lethargy, transient weakness and/or tetany, paresthesiae, thirst and joint pains due to chondrocalcinosis. Blood pressure is usually lower than normal. Sudden cardiac arrest has been reported.
Because of this variability, management cannot be protocol driven and must be individualized according to response and biochemical severity.
Mutations in SLC12A3, encoding the thiazide-sensitive NaCl cotransporter, are found in most GS patients. In a small minority, mutations in CLCNKB render the correct diagnosis of Type 3 Bartter Syndrome (T3BS).
- Clinical Diagnosis
lethargy, muscle weakness/pain, paresthesiae, tetany (all may be variable/transient) palpitations
- thirst/polydipsia, salt craving (usually patients prefer salty to sweet treats in childhood)
- joint pain
- diuretic/laxative/PPI use, (whether prescribed or over-the-counter)
blood K (low),
Mg (variably low),
Send spot urine calcium:creatinine ratio (low)
BP low but rises with age
Refer to regional centre if ≥ 3 abnormalities and not on above drugs.
renin / aldosterone (raised / raised if K not low)
diuretic / laxative screen
urine Cl if diagnosis doubtful (low in vomiting/laxative abuse)
renal u/s (exclude nephrocalcinosis)
- genetic testing – see below
1. Support electrolytes directly (lifelong) Requirements for K / Mg are variable and must be individually tailored, and may be very high.
Salt: encourage liberal addition of salt to food, and high potassium/magnesium diet.
Potassium: KCl better than effervescent K. Can be given as tabs or liquid. Usually less symptomatic if K >3. K will not rise until Mg does. SlowK™ and Kay-Cee-L Liquid™ are preferable to SandoK™. SlowK is currently not available. A prescription for “slow release KCL 600 mg” with the dose will enable pharmacists to obtain an equivalent through IDIS.
Magnesium: This is difficult as all Mg preparations cause diarrhoea and they differ in bio-availability. Aim for Mg > 0.6 to minimise symptoms. Trial and error (from a starting point of Mg glycerophosphate or lactate at 3–5 mg/kg/24 hrs, divided in 2–4 doses) is necessary.
Lactate: (Magtab SR) is slow-release and often better tolerated/more effective, therefore dosage lower. Also only requires bd prescription. A few patients require intermittent iv Mg and/or K boluses; however benefits may be short-lived. Over dosage of K/Mg is very unlikely unless CKD coexists. Patient tolerance is the usual limiting factor.
Doses usually require increase during periods of intercurrent infections, especially those involving vomiting and diarrhoea. In case of acute tetany, 20% MgCl2 should be administered IV (0.1 mmol Mg/kg per dose) every 6 hours prn, together with K as necessary.
(See Dietary Needs)
2. Support electrolytes indirectly (individualise)
K: amiloride, spironolactone/eplerenone, ACE inhibitors/ARBs, beta blockers.
Can be useful to decrease electrolyte requirements. Doses often limited by BP drop and/or other side effects
Vitamin D (may help Mg)
Investigate cardiac rhythm symptoms w/ 24 hour tape
Maintain a high salt, high magnesium and high potassium diet
May require NSAIDs for chondrocalcinosis (indomethacin NOT otherwise indicated
Working with Dr Jasmeet Soar (an anaesthetist), Drs Hugh Gallagher and Charlie Tomson have written a clinical guideline for the perioperative management of people with inherited saltwasting alkaloses(Gitelman’s syndrome and Bartter’s syndrome) undergoing non-urgent surgical procedures. It includes recommendations on pre-operative assessment, minimum acceptable levels of potassium and magnesium and intra- and post- procedural monitoring. The guideline has been endorsed by the Renal Association and the Royal College of Anaesthetists. The aim is to improve the current inconsistent approach whereby patients with saltwasting alkaloses may be denied surgery on the basis of chronic and stable metabolic abnormalities.
1-2 x yearly at regional centre.
Plus 1-3 monthly K, Mg, bicarb measurements at local centre/GP, more often if any instability.
At each visit complaints related to hypokalemia (fatigue, muscle weakness, constipation, cardiac arrhythmias) and hypomagnesemia (tetany, cramps, paresthesias, joint and muscle pain) should be evaluated.
GS patients should be encouraged to keep their own results tables and increase K/Mg doses as a first-line if unwell. Like people with diabetes, most can learn to self-manage as long as data are available to them (e.g. PatientView). Daily activities may be symptom-limited and some occupations are unsuitable (e.g. active armed forces, pilot).
Hypertension, proteinuria, FSGS, CKD. These require specialist investigation.
- Genetic Testing
SLC12A3 testing (UKGTN-approved), with or without CLCNKB, can be requested by consultants, via forms available here.
Since GS is a recessive trait, the recurrence risk for parents with an affected child is 25%. If parents already have other children who are not obviously affected, this does not exclude GS because clinical symptoms can appear later in life. If the mutations in their affected child are known, specific DNA testing of other child(ren) may be performed. Adults with GS have a low risk of having children with GS (~1 in 400) unless patient and his/her partner are consanguineous.
Although technically feasible, antenatal diagnosis for GS is not usually offered because of the good prognosis in the majority of cases.
Written by the Hypokalaemic Alkaloses Rare Disease Group